The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Colorectal Cancer Immunotherapy: Options and Strategies
Open accessAbstract
Colorectal cancer is the third most common cancer in the world with increasing incidence and mortality rates globally. Standard treatments for colorectal cancer have always been surgery, chemotherapy and radiotherapy which may be used in combination to treat patients. However, these treatments have many side effects due to their non-specificity and cytotoxicity toward any cells including normal cells that are growing and dividing. Furthermore, many patients succumb to relapse even after a series of treatments. Thus, it is crucial to have more alternative and effective treatments to treat CRC patients. Immunotherapy is one of the new alternatives in cancer treatment. The strategy is to utilize patients' own immune systems in combating the cancer cells. Cancer immunotherapy overcomes the issue of specificity which is the major problem in chemotherapy and radiotherapy. The normal cells with no cancer antigens are not affected. The outcomes of some cancer immunotherapy have been astonishing in some cases, but some which rely on the status of patients' own immune systems are not. Those patients who responded well to cancer immunotherapy have a better prognostic and better quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“In the 20th century, the FDA has approved various types of immunotherapeutic drugs including Sipuleucel-T, a cancer vaccine to treat castration-resistant prostate cancer in 2010 (41, 42).”
BackgroundGlobal patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228
Inflammatory responses and inflammation-associated diseases in organs
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2018) · Oncotarget · doi:10.18632/oncotarget.23208 · Cited by 5,143
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,806
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“This, in turn, activates more immune cells and other immune signalings, leading to excessive immune responses and toxicities (138).”
BackgroundTalimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
Steinman, R. M., & Cohn, Z. A. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.137.5.1142 · Cited by 2,424
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · cited 1×
“Adoptive cell transfer that uses TILs (ACT-TIL) was first successfully observed in 60% of metastatic melanoma patients who had not been treated with interleukin-2 (IL-2) and 40% of non-respondents IL-2 treatments which resulted in cancer regression (123).”
BackgroundCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“The role of CTLA-4 in cancer immunotherapy was discovered through antibody generation that specifically targets the CTLA-4 glycoprotein (94).”
BackgroundScott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Derivation of specific antibody‐producing tissue culture and tumor lines by cell fusion
Köhler, G., & Milstein, C. (1976) · European Journal of Immunology · doi:10.1002/eji.1830060713 · Cited by 1,922
Kiessling, R., Klein, E., & Wigzell, H. (1975) · European Journal of Immunology · doi:10.1002/eji.1830050208 · Cited by 1,824
Mesorectal excision for rectal cancer
MacFarlane, J. K., Ryall, R. D. H., & Heald, R. J. (1993) · The Lancet · doi:10.1016/0140-6736(93)90207-w · Cited by 1,781
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,715
The Concept of Immunological Surveillance
Burnet, F. M. (2015) · Progress in Tumor Research · doi:10.1159/000386035 · Cited by 1,656
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., et al. (2002) · Nature · doi:10.1038/415536a · Cited by 1,472
A Randomized Trial of Laparoscopic versus Open Surgery for Rectal Cancer
Bonjer, H. J., Deijen, C. L., Abis, G. A., Cuesta, M. A., van der Pas, M. H. G. M., de Lange-de Klerk, E. S. M., Lacy, A. M., Bemelman, W. A., Andersson, J., Angenete, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414882 · Cited by 1,437
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Gong, J., Chehrazi-Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,273
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,179
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,148
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Kiessling, R., Klein, E., Pross, H., & Wigzell, H. (1975) · European Journal of Immunology · doi:10.1002/eji.1830050209 · Cited by 1,143
Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 982
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5538 · Cited by 951
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 913
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Therapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. (2017) · Nature · doi:10.1038/nature22395 · Cited by 879
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
Scanlan., M. J., Gure., A. O., Jungbluth., A. A., Old., L. J., & Chen., Y. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18803.x · Cited by 873
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 856
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Patnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 807
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752 · cited 1×
“Thus, T cells are likely to experience anergy, exhaustion, senescence and stemness, making it a challenge to achieve the desired CAR-T cells tumor killing (155).”
BackgroundThe toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy, E. F. (2006) · Europe PMC (PubMed Central) · Cited by 747
Klein, G., Sjögren, H. O., Klein, E., & Hellström, K. E. (1960) · PubMed · Cited by 742
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 715
Lipman, N. S., Jackson, L. R., Trudel, L. J., & Weis-Garcia, F. (2005) · ILAR Journal · doi:10.1093/ilar.46.3.258 · Cited by 644
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7379 · Cited by 631
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Siddiqi, T., Chavez, J. C., Hosing, C. M., Ghobadi, A., Budde, L. E., Bot, A., Rossi, J. M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.020 · Cited by 620
Senzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
Lamm, D. L., Blumenstein, B. A., Crawford, E. D., Montie, J. E., Scardino, P., Grossman, H. B., Stanisic, T. H., Smith, J. A., Sullivan, J., Sarosdy, M. F., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251703 · Cited by 605
Isaacs, A., & Lindenmann, J. (2015) · The Journal of Immunology · doi:10.1093/jimmunol/195.5.1911 · Cited by 602
Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Wang, G., Lu, X., Dey, P., Deng, P., Wu, C. C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0224 · Cited by 553
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Brekke, O. H., & Sandlie, I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd984 · Cited by 550
Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549 · cited 1×
“Such scenarios are seen in many cases of cancers and suppressor T cells such as T regulatory cells, suggesting the reason for lack of immune responses in cancer patients (101, 102).”
BackgroundKilling Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
Established cell line of urinary bladder carcinoma (T24) containing tumour‐specific antigen
Bubeník, J., Barešová, M., Viklický, V., Jakoubková, J., Sainerová, H., & Donner, J. (1973) · International Journal of Cancer · doi:10.1002/ijc.2910110327 · Cited by 525
(2019) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · doi:10.1200/jco · Cited by 522
Current Progress in CAR-T Cell Therapy for Solid Tumors
Ma, S., Li, X., Wang, X., Cheng, L., Li, Z., Zhang, C., Ye, Z., & Qian, Q. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.34213 · Cited by 496
Ogura, A., Konishi, T., Cunningham, C., Garcia-Aguilar, J., Iversen, H., Toda, S., Lee, I. K., Lee, H. X., Uehara, K., Lee, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00032 · Cited by 491
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
The Intriguing History of Cancer Immunotherapy
Dobosz, P., & Dzieciątkowski, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02965 · Cited by 458
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Zhang, C., Wang, Z., Yang, Z., Wang, M., Li, S., Li, Y., Zhang, R., Xiong, Z., Wei, Z., Shen, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.010 · Cited by 451
Coley, W. B. (1910) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591571000301601 · Cited by 423
Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0348-2 · Cited by 418
Engineered T Cell Therapy for Cancer in the Clinic
Zhao, L., & Cao, Y. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02250 · Cited by 410
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., & Raulet, D. H. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 394
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
Lamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. W. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 368
Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., & Honjo, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003208 · Cited by 342
Talimogene laherparepvec: First in class oncolytic virotherapy
Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1412896 · Cited by 335
PD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 334
Hege, K. M., Bergsland, E. K., Fisher, G. A., Nemunaitis, J. J., Warren, R. S., McArthur, J. G., Lin, A. A., Schlom, J., June, C. H., & Sherwin, S. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0222-9 · Cited by 325
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 298
Kershaw, M. H., Wang, G., Westwood, J. A., Pachynski, R. K., Tiffany, H. L., Marincola, F. M., Wang, E., Young, H. A., Murphy, P. M., & Hwu, P. (2002) · Human Gene Therapy · doi:10.1089/10430340260355374 · Cited by 297
Kong, Y., Zhu, L., Schell, T. D., Zhang, J., Claxton, D. F., Ehmann, W. C., Rybka, W. B., George, M. R., Zeng, H., & Zheng, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2626 · Cited by 297
Ishida, T., Ishii, T., Inagaki, A., Yano, H., Komatsu, H., Iida, S., Inagaki, H., & Ueda, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0261 · Cited by 291
Tran, K. Q., Zhou, J., Durflinger, K. H., Langhan, M. M., Shelton, T. E., Wunderlich, J. R., Robbins, P. F., Rosenberg, S. A., & Dudley, M. E. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31818403d5 · Cited by 287
Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02031 · Cited by 285
Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
Kisielow, M., Kisielow, J., Capoferri-Sollami, G., & Karjalainen, K. (2005) · European Journal of Immunology · doi:10.1002/eji.200526090 · Cited by 271
Burch, P. A., Breen, J. K., Buckner, J. C., Gastineau, D. A., Kaur, J. A., Laus, R., Padley, D. J., Peshwa, M. V., Pitot, H. C., Richardson, R. L., et al. (2000) · PubMed · Cited by 260
Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1)
Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M., & Honjo, T. (1994) · Genomics · doi:10.1006/geno.1994.1562 · Cited by 253
IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS
BURNET, M. (1964) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a070310 · Cited by 239
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Lee, H. T., Lee, S. H., & Heo, Y.-S. (2019) · Molecules · doi:10.3390/molecules24061190 · Cited by 233
Gulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228
Adoptive T Cell Immunotherapy For Cancer
Perica, K., Varela, J. C., Oelke, M., & Schneck, J. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10179 · Cited by 224
Hodge, J. W., McLaughlin, J. P., Kantor, J. A., & Schlom, J. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00238-1 · Cited by 201
Kettleborough, C. A., Saldanha, J., Heath, V. J., Morrison, C. J., & Bendig, M. M. (1991) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/4.7.773 · Cited by 197
Microsatellite instability in colorectal cancer
Nojadeh, J. N., Sharif, S. B., & Sakhinia, E. (2018) · EXCLI journal · doi:10.17179/excli2017-948 · Cited by 196
DiPaola, R., Plante, M., Kaufman, H., Petrylak, D., Israeli, R., Lattime, E., Manson, K., & Schuetz, T. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-1 · Cited by 191
Burch, P. A., Croghan, G. A., Gastineau, D. A., Jones, L. A., Kaur, J. S., Kylstra, J. W., Richardson, R. L., Valone, F. H., & Vuk‐Pavlović, S. (2004) · The Prostate · doi:10.1002/pros.20040 · Cited by 190
Rentsch, C. A., Birkhäuser, F. D., Biot, C., Gsponer, J. R., Bisiaux, A., Wetterauer, C., Lagranderie, M., Marchal, G., Orgeur, M., Bouchier, C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.061 · Cited by 188
Speetjens, F. M., Kuppen, P. J. K., Welters, M. J. P., Essahsah, F., Voet van den Brink, A. M. E. G., Lantrua, M. G. K., Valentijn, A. R. P. M., Oostendorp, J., Fathers, L. M., Nijman, H. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2227 · Cited by 185
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy
Ramos, C. A., & Dotti, G. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.573476 · Cited by 182
Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street
Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 180
Kageyama, S., Ikeda, H., Miyahara, Y., Imai, N., Ishihara, M., Saito, K., Sugino, S., Ueda, S., Ishikawa, T., Kokura, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1559 · Cited by 179
Joller, N., & Kuchroo, V. K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_62 · Cited by 174
Clinical relevance of colorectal cancer molecular subtypes
Rodríguez-Salas, N., Dominguez, G., Barderas, R., Mendiola, M., García‐Albéniz, X., Maurel, J., & Batlle, J. F. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.007 · Cited by 169
DeMaria, P. J., & Bilušić, M. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.001 · Cited by 166
McDermott, D. F., Cheng, S., Signoretti, S., Margolin, K. A., Clark, J. I., Sosman, J. A., Dutcher, J. P., Logan, T. F., Curti, B. D., Ernstoff, M. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1520 · Cited by 160
Driving T-cell immunotherapy to solid tumors
Garber, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4090 · Cited by 159
Kitano, A., Ono, M., Yoshida, M., Noguchi, E., Shimomura, A., Shimoi, T., Kodaira, M., Yunokawa, M., Yonemori, K., Shimizu, C., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000150 · Cited by 158
Cellular Basis of the Immunological Defects in Thymectomized Mice
Miller, J. F. A. P., Mitchell, G. F., & WEISS, N. S. (1967) · Nature · doi:10.1038/214992a0 · Cited by 155
Pehlivan, K. C., Duncan, B. B., & Lee, D. W. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0470-x · Cited by 153
Nixon, N. A., Blais, N., Ernst, S., Kollmannsberger, C., Bebb, G. D., Butler, M. O., Smylie, M., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.3840 · Cited by 153
Morse, M. A., Niedzwiecki, D., Marshall, J. L., Garrett, C. H., Chang, D. Z., Aklilu, M., Crocenzi, T. S., Cole, D. J., Dessureault, S., Hobeika, A. C., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318292919e · Cited by 150
CD28: a signalling perspective
WARD, S. G. (1996) · Biochemical Journal · doi:10.1042/bj3180361 · Cited by 149
The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
Jørgensen, N., Persson, G., & Hviid, T. V. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00911 · Cited by 149
Butterfield, L. H., & 易宗毕 (2015) · doi:10.3760/cma.j.issn.1007-9742.2015.11.117 · Cited by 144
Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger, J. C., Ridge, N. A., Marszalowicz, G. P., Prajapati, P., Hersperger, A. R., Waldman, S. A., & Snook, A. E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0362 · Cited by 143
Beer, T. M., Bernstein, G. T., Corman, J. M., Glodé, L. M., Hall, S. J., Poll, W. L., Schellhammer, P. F., Jones, L. A., Xu, Y., Kylstra, J. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3223 · Cited by 136
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma
Starzyñska, T., Marsh, P., Schofield, P. F., Roberts, S., Myers, K. A., & Stern, P. L. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.173 · Cited by 133
Xu, Y., Yang, Z., Horan, L. H., Zhang, P., Liu, L., Zimdahl, B., Green, S., Lu, J., Morales, J. F., Barrett, D. M., et al. (2018) · Cell Discovery · doi:10.1038/s41421-018-0066-6 · Cited by 132
Colorectal cancer and immunity: What we know and perspectives
Pernot, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3738 · Cited by 131 · cited 2×
“Many immune checkpoint inhibitor drugs are targeting CTLA-4 that is designed to bind and block this protein, thus allow CD28 binding to MHC and stimulate T cell immune response, activate downstream immune signaling and destroy the malignant cells (103, 104).”
BackgroundCancer Immunotherapy: Sipuleucel‐T and Beyond
Hammerstrom, A. E., Cauley, D. H., Atkinson, B. J., & Sharma, P. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.8.813 · Cited by 123
Miao, H., Choi, B. D., Suryadevara, C. M., Sanchez-Perez, L. A., Yang, S., Leon, G. D., Sayour, E. J., McLendon, R. E., Herndon, J. E., Healy, P. N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094281 · Cited by 122
Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Kaufman, H. L., Lenz, H., Marshall, J. L., Singh, D., Garrett, C. R., Cripps, C., Moore, M. J., von Mehren, M., Dalfen, R., Heim, W. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0276 · Cited by 122
Immunotherapy in hematologic malignancies: past, present, and future
Im, A., & Pavletic, S. Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0453-8 · Cited by 114
Schlom, J., Hodge, J. W., Palena, C., Tsang, K.-Y., Jochéms, C., Greiner, J. W., Farsaci, B., Madan, R. A., Heery, C. R., & Gulley, J. L. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00002-0 · Cited by 111
Bilusic, M., Heery, C. R., Arlen, P. M., Rauckhorst, M., Apelian, D., Tsang, K. Y., Tucker, J. A., Jochems, C., Schlom, J., Gulley, J. L., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1505-8 · Cited by 102
Talimogene Laherparepvec: Review of its Mechanism of Action and Clinical Efficacy and Safety
Raman, S. S., Hecht, J. R., & Chan, E. (2019) · Immunotherapy · doi:10.2217/imt-2019-0033 · Cited by 102
Tang, X.-Y., Sun, Y., Zhang, A., Hu, G., Cao, W. W., Wang, D., Zhang, B., & Chen, H. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-013904 · Cited by 97
Cytokines and Interferons: Types and Functions
Ferreira, V. L., Borba, H. H. L., Bonetti, A. D. F., Leonart, L. P., & Pontarolo, R. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.74550 · Cited by 97
Fehleisen, N. (1882) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0029-1196806 · Cited by 96
Back to the Colorectal Cancer Consensus Molecular Subtype Future
Menter, D. G., Davis, J. S., Broom, B. M., Overman, M. J., Morris, J. S., & Kopetz, S. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0674-9 · Cited by 96
Pituch, K. C., Miska, J. M., Krenciute, G., Panek, W. K., Li, G., Rodríguez-Cruz, T., Wu, M., Han, Y., Lesniak, M. S., Gottschalk, S. M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.001 · Cited by 94
Stadtmauer, E. A., Faitg, T. H., Lowther, D. E., Badros, A. Z., Chagin, K., Dengel, K., Iyengar, M. K., Melchiori, L., Navenot, J., Norry, E., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000194 · Cited by 93
Shindo, Y., Yoshimura, K., Kuramasu, A., Watanabe, Y., Ito, H., Kondo, T., Oga, A., Ito, H., Yoshino, S., Hazama, S., et al. (2015) · PubMed · Cited by 90
The 2018 Nobel Prize in medicine goes to cancer immunotherapy
Guo, Z. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-5020-3 · Cited by 89
Zhang, B.-L., Li, D., Gong, Y.-L., Huang, Y., Qin, D.-Y., Jiang, L., Liang, X., Yang, X., Gou, H.-F., Wang, Y.-S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.229 · Cited by 88
Bishop, M. R., Maziarz, R. T., Waller, E. K., Jaeger, U., Westin, J. R., McGuirk, J. P., Fleury, I., Holte, H., Borchmann, P., del Corral, C., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000151 · Cited by 88
Garg, M. B., Lincz, L. F., Adler, K., Scorgie, F. E., Ackland, S. P., & Sakoff, J. A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.421 · Cited by 78
Prostatic acid phosphatase expression in human tissues.
Graddis, T. J., McMahan, C. J., Tamman, J., et al. (2011) · PubMed · Cited by 75
Overexpressed oncogenic tumor-self antigens: New vaccine targets
Bright, R. K., Bright, J. D., & Byrne, J. A. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29475 · Cited by 75
Chi, X., Yang, P., Zhang, E., Gu, J., Xu, H., Li, M., Gao, X., Li, X., Zhang, Y., Xu, H., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2361 · Cited by 75
Strategies used for MUC1 immunotherapy: preclinical studies
Tang, C.-K., & Apostolopoulos, V. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.951 · Cited by 74
Kerkar, S. P., Wang, Z.-F., Lasota, J. P., Park, T. S., Patel, K. J., Groh, E. M., Rosenberg, S. A., & Miettinen, M. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000119 · Cited by 74
Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo.
Deng, X., Gao, F., Li, N., Li, Q., Zhou, Y., Yang, T., Cai, Z., Du, P., Chen, F., & Cai, J. (2019) · PubMed · Cited by 73
Strategies used for MUC1 immunotherapy: human clinical studies
Tang, C.-K., Κατσάρα, Μ., & Apostolopoulos, V. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.963 · Cited by 71
Kantoff, P. W., Gulley, J. L., & Navarro, C. P. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.7748 · Cited by 67
Michaud, H., Eliaou, J., Lafont, V., Bonnefoy, N., & Gros, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955684 · Cited by 63
Biesma, B., Willemse, P., Mulder, N., Verschueren, R. C. J., Kema, I., de Bruijn, H. W. A., Postmus, P. E., Sleijfer, D., & de Vries, E. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.372 · Cited by 59
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
García-Martínez, E., Smith, M. M., Buqué, A., Aranda, F., de la Peña, F. A., Rubio, A. I., Cánovas, M. S., Conesa, M. A. V., Fucikova, J. P., Špíšek, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433982 · Cited by 58
BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.
Lamm, D. L. (1995) · PubMed · Cited by 55
State of the Art in Tumor Antigen and Biomarker Discovery
Even-Desrumeaux, K., Baty, D., & Chames, P. (2011) · Cancers · doi:10.3390/cancers3022554 · Cited by 52
Prostatic acid phosphatase expression in human tissues
Graddis, T. J., McMahan, C. J., Tamman, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/diag-10-b29 · Cited by 51
Hensel, J. A., Khattar, V., Ashton, R., & Ponnazhagan, S. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.12.004 · Cited by 47
The Promise of Preventive Cancer Vaccines
Lollini, P., Cavallo, F., Nanni, P., & Quaglino, E. (2015) · Vaccines · doi:10.3390/vaccines3020467 · Cited by 46
Dores, G. M., Bryant-Genevier, M. G., & Pérez-Vilar, S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.9249 · Cited by 46
MAGE-A3 is highly expressed in a subset of colorectal cancer patients.
Kumara, H. M. C. S., Grieco, M. J., Caballero, O. L., et al. (2012) · PubMed · Cited by 44
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
Henick, B. S., Herbst, R. S., & Goldberg, S. B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.955794 · Cited by 43
Lázaro‐Gorines, R., Ruiz‐de‐la‐Herrán, J., Navarro, R., Sanz, L., Álvarez‐Vallina, L., Martínez‐del‐Pozo, Á., Gavilanes, J. G., & Lacadena, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-48285-z · Cited by 42
Hollinshead, A. C., Elias, E. G., Arlen, M., Buda, B. S., Mosley, M., & Scherrer, J. (1985) · Cancer · Cited by 40
T Cell Receptor Signaling Can Directly Enhance the Avidity of CD28 Ligand Binding
Sánchez-Lockhart, M., Rojas, A. V., Fettis, M. M., Bauserman, R. G., Higa, T. R., Miao, H., Waugh, R. E., & Miller, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089263 · Cited by 40
EpCAM-Expressing Circulating Tumor Cells in Colorectal Cancer
Nicolazzo, C., Raimondi, C., Francescangeli, F., Ceccarelli, S., Trenta, P., Magri, V., Marchese, C., Zeuner, A., Gradilone, A., & Gazzaniga, P. (2017) · The International Journal of Biological Markers · doi:10.5301/ijbm.5000284 · Cited by 38
Immunotherapy as an Option for Cancer Treatment
Rusch, T., Bayry, J., Werner, J., Shevchenko, I., & Bazhin, A. V. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0491-5 · Cited by 36
Saha, A., Chatterjee, S. K., Foon, K. A., Celis, E., & Bhattacharya‐Chatterjee, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3045 · Cited by 34
Chesney, J. A., Puzanov, I. J., Collichio, F. A., Milhem, M. M., Hauschild, A., Chen, L., Sharma, A., Garbe, C., Singh, P. P., & Mehnert, J. M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0530-6 · Cited by 32
Simplified MSI marker panel for diagnosis of colorectal cancer.
Shemirani, A. I., Haghighi, M. M., Zadeh, S. M., Fatemi, S. R., Taleghani, M. Y., Zali, N., Akbari, Z., Kashfi, S. M. H., & Zali, M. R. (2011) · PubMed · Cited by 25
Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression
Yanagi, T., Nagai, K., Shimizu, H., & Matsuzawa, S. (2017) · Oncotarget · doi:10.18632/oncotarget.19497 · Cited by 25
Prognostic value of MAGE-A9 expression in patients with colorectal cancer
Zhan, W., Zhang, Z., Zhang, Y., Ma, J., Wu, T., Gu, Y., Li, Y., & Yang, J. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.08.005 · Cited by 17
Besneux, M., Greenshields‐Watson, A., Scurr, M. J., MacLachlan, B. J., Christian, A. D., Davies, M. M., Hargest, R., Phillips, S. M., Godkin, A. J., & Gallimore, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2266-1 · Cited by 17
Aberrant expression of Rab1A and its prognostic significance in human colorectal cancer.
Wang, Z.-K., Cheng, Z.-W., Chen, S.-J., Xg, Z., Gu, Y.-P., Xd, Y., Sun, L.-Q., Liu, W.-T., Zhang, Y.-J., Yuan, J.-F., et al. (2018) · PubMed · doi:10.26355/eurrev_201807_15505 · Cited by 11
Alatrash, G., Crain, A. K., & Molldrem, J. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812630-1.00007-4 · Cited by 10
The Effect of vaccine on cancer patients
Graham, J., & Graham, R. M. (1959) · Plastic & Reconstructive Surgery · doi:10.1097/00006534-195911000-00016 · Cited by 8
Nojadeh, J. N., Hashemzadeh, S., Kafil, H. S., Sharif, S. B., Eftekharsadat, A., Ghasemnejad, T., Ghojazadeh, M., & Sakhinia, E. (2018) · EXCLI journal · doi:10.17179/excli2018-1455 · Cited by 6
Cited by
Wang, H., Tian, T., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168470 · Cited by 364
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Wang, L., Li, S., Luo, H., Lu, Q., & Yu, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02477-0 · Cited by 271
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296341 · Cited by 216
Kamrani, A., Nasiri, H., Hassanzadeh, A., Ahmadian Heris, J., Mohammadinasab, R., Sadeghvand, S., Sadeghi, M., Valedkarimi, Z., Hosseinzadeh, R., Shomali, N., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01430-8 · Cited by 50
Metadata
- Authors
- Johdi, N. A., & Sukor, N. F.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-18
- Volume
- 11
- Pages
- 1624-1624
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3087639804
- Cited by
- 452
- References
- 201
- FWCI
- 18.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.